NeuroTalk Support Groups - View Single Post

mrsD · 12-10-2010, 06:37 AM

Trileptal is a modified form of Tegretol. Both drugs can cause hyponatremia (low sodium), and so can SSRI drugs.

Combined you will have to be monitored closely for this side effect.
Cymbalta:

Quote:

Although infrequent, several cases of duloxetine-induced hyponatremia have been reported. In one case report, duloxetine-induced hyponatremia was confirmed after inadvertent rechallenge. It has been suggested that there is a dose-related effect in the development of hyponatremia with duloxetine.

Numerous cases of hyponatremia have been reported following treatment with a selective serotonin reuptake inhibitor (SSRI). Risk factors for the development of SSRI-associated hyponatremia including advanced age, female gender, concomitant use of diuretics, low body weight, and lower baseline serum sodium levels have been identified. Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) and typically resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment (e.g., water restriction, dietary sodium). The proposed mechanism for the development of hyponatremia involves the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) via release of antidiuretic hormone.

Metabolic side effects have infrequently included hyponatremia

from http://www.drugs.com/sfx/cymbalta-side-effects.html

Trileptal:

Quote:

Oxcarbazepine (Includes Trileptal) ↔ Hyponatremia

Moderate Potential Hazard, High plausibility

Applies to: Hyponatremia, Renal Dysfunction, SIADH, Fluid Retention, Adrenal Insufficiency, Hypothyroidism, Polydipsia, Cirrhosis, Congestive Heart Failure

Clinically significant hyponatremia (Na < 125 mmol/L) can develop during the use of oxcarbazepine. In controlled studies, 2.5% of patients receiving oxcarbazepine developed hyponatremia at some point during treatment, generally within the first 3 months but as late as a year or more after initiating therapy. In most cases, the hyponatremia was asymptomatic and serum sodium levels normalized within a few days following withdrawal of the medication without additional treatment. Therapy with oxcarbazepine should be administered cautiously in patients with conditions predisposing to hyponatremia, such as SIADH, use of diuretics or drugs associated with inappropriate antidiuretic hormone secretion, adrenal insufficiency, hypothyroidism, primary polydipsia, and edema (e.g., due to liver cirrhosis, congestive heart failure, or nephrotic syndrome). Serum sodium levels should be monitored during maintenance therapy, and patients should be monitored for signs and symptoms possibly indicating hyponatremia such as nausea, malaise, headache, lethargy, confusion, obtundation, and increase in seizure frequency or severity. If hyponatremia occurs, conservative measures such as fluid restriction, a reduction in dosage, or discontinuation of therapy will usually suffice.

from http://www.drugs.com/disease-interac...trileptal.html

Trileptal is a much more common cause of hyponatremia than SSRIs, but it can be additive when used together.
More here:
http://www.drugs.com/drug-interactio...trileptal.html

So if you decide to use this drug, make sure you understand the signs to look for and report to doctor immediately. Blood electrolyte monitoring is a good precaution periodically.